NCT06583837View on ClinicalTrials.gov

Orelabrutinib Followed by Response-adapted Ultra-low Dose 4Gy Radiation as First-line Treatment of MALT Lymphoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2028

Conditions
Lymphoma, B-Cell, Marginal Zone
Interventions
DRUG

Orelabrutinib

Orelabrutinib was administrated for 12 weeks

RADIATION

response-adapted radiation

response-adapted ultra-low dose 4Gy radiation

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER